Breaking News

VIVEbiotech Secures Investment to Expand Lentiviral Vector Manufacturing

Will support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor

VIVEbiotech, a lentiviral vector Contract Development and Manufacturing Organization (CDMO), has announced a growth equity investment from Ampersand Capital Partners that will enable the expansion of its lentiviral vector manufacturing capabilities in San Sebastian, Gipuzkoa, Spain and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.   VIVEbiotech provides process development, manufacturing and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters